Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of HLX208 in BRAF V600-mutant advanced melanoma
CTR20212770Phase 2Active
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208 in melanoma, sponsored by Suzhou Runxin Biotechnology. Started Mar 2022; status: active.
02
Drugs
HLX208
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20212770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212770.